Avacta shares drop 30% after lateral flow test blow
Shares in cancer therapies and diagnostics company Avacta (AVCT:AIM) sank 30% to 81.4p after it said laboratory analysis showed its proprietary lateral flow test was less effective at detecting lower viral loads of the Omicron...
10 January 2022